Thomas K. Equels, Executive Vice Chairman, states, "European Medicines Agency designation of Ampligen(R)/rintatolimod as an orphan drug is an important achievement in our path seeking commercial approval of
The QIDP and Fast Track designations are for the use of CD101 IV in the treatment of candidemia and invasive candidiasis. The QIDP designation, provided under the Generating
The Company expects patient recruitment in the second Phase 3 trial investigating Fovista in combination with Lucentis to be completed approximately by the end of the third quarter
Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of
OSE CEO Dominique Costantini said: "This collaboration represents a significant step as first licensing and distribution agreement in the business development strategy for OSE Pharma with pharmaceutical companies
Under the settlement and license agreement, Horizon has granted Perrigo the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under
Akynzeo is the first approved fixed dose combination oral agent that targets two critical signalling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron,
The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox
"For the first time, we have looked at the Scale clinical trial programme to explore to what degree the benefits of liraglutide 3 mg could be assigned to
The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.